Pacific Biosciences of California has lowered its full-year 2026 revenue guidance to between $155 million and $165 million and now expects to reach cash flow breakeven in 2028, a year later than previously anticipated. The company reported second-quarter revenue of $39 million, roughly flat compared with $39.8 million a year earlier, while non-GAAP gross margin came in at 36 percent. PacBio also announced that Chief Operating Officer Mark Van Oene has taken over as President and Chief Executive Officer, replacing Christian Henry effective immediately, and is implementing a leaner organizational structure focused on clinical workflows and the rollout of SPRQ-Nx chemistry. Non-GAAP operating expenses for the year are projected at $215 million to $220 million, and full-year consumables pull-through per Revio system is now expected to be $200,000 to $225,000. The company cited SPRQ-Nx transition headwinds and compute cost inflation as factors weighing on near-term performance.
Pacific Biosciences of CaliforniaLowered 2026 revenue guidance and delayed cash flow breakeven to 2028.
